<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04922515</url>
  </required_header>
  <id_info>
    <org_study_id>PDA-MAPS</org_study_id>
    <nct_id>NCT04922515</nct_id>
  </id_info>
  <brief_title>Pancreatic Ductal Adenocarcinoma - Microbiome as Predictor of Subtypes</brief_title>
  <acronym>PDA-MAPS</acronym>
  <official_title>Pancreatic Ductal Adenocarcinoma - Microbiome as Predictor of Subtypes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Goettingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Goettingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prospective clinical trial &quot;PDA-MAPS - Pancreatic ductal adenocarcinoma - Microbiome as&#xD;
      Predictor of Subtypes&quot; aims to investigate the prognostic and predictive power of the&#xD;
      orointestinal and tumoral microbiome in PDAC patients and associate findings with genetic,&#xD;
      transcriptional and clinical data, in particular with treatment response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prospective clinical trial &quot;PDA-MAPS - Pancreatic ductal adenocarcinoma - Microbiome as&#xD;
      Predictor of Subtypes&quot; aims to investigate the prognostic and predictive power of the&#xD;
      orointestinal and tumoral microbiome in PDAC patients and associate findings with genetic,&#xD;
      transcriptional and clinical data, in particular with treatment response. Patients with&#xD;
      histologically confirmed PDA are enrolled at primary diagnosis and prior to oncological or&#xD;
      surgical treatment. Rectal and buccal microbiome swabs as well as detailed clinical records&#xD;
      are obtained from all patients. Following DNA extraction, both 16S rRNA and metagenomic&#xD;
      sequencing will be performed using ONT sequencing platform. All data and clinical records are&#xD;
      centrally stored, visualized and integrated via tranSMART and SEEK platforms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 25, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>12 months upon study enrollment</time_frame>
    <description>Progression free survival of patients measured in months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Molecular subtypes of pancreatic cancer</measure>
    <time_frame>within 3 months of histological diagnosis</time_frame>
    <description>Basal and classical subtype via RNAseq from tissue samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to chemotherapy</measure>
    <time_frame>up to 6 months after start of therapy</time_frame>
    <description>reponse, partial response and progress according to RECIST within 6 months of therapy initiation</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Pancreatic Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oral and rectal swabs for microbiome sequencing</intervention_name>
    <description>Oral swabs and rectal swabs are collected non-invasively.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Patients with pancreatic mass suspicious of pancreatic ductal adenocarcinoma&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt; 18 years&#xD;
&#xD;
          -  patients that cannot give informed consent&#xD;
&#xD;
          -  pregnant and breastfeeding women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albrecht Neesse, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medicine Goettingen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Albrecht Neesse, MD, PhD</last_name>
    <phone>0049 551 39</phone>
    <phone_ext>62313</phone_ext>
    <email>albrecht.neesse@med.uni-goettingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christoph Ammer-Herrmenau, MD</last_name>
    <email>christoph.herrmenau@med.uni-goettingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Centre Goettingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albrecht Neesse, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Centre Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Volker Ellenrieder, MD</last_name>
      <phone>0049 551 39</phone>
      <phone_ext>62313</phone_ext>
      <email>volker.ellenrieder@med.uni-goettingen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 31, 2021</study_first_submitted>
  <study_first_submitted_qc>June 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2021</study_first_posted>
  <last_update_submitted>June 5, 2021</last_update_submitted>
  <last_update_submitted_qc>June 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Goettingen</investigator_affiliation>
    <investigator_full_name>Albrecht Neesse</investigator_full_name>
    <investigator_title>https://gastroenterologie.umg.eu/ueber-uns/team/neesse/</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

